Skip to main content
Retour
Watch Compare

Cartesian Therapeutics, Inc.

Qualité des données : 100%
RNAC
Nasdaq Manufacturing Chemicals
6,25 €
▲ 0,10 € (1,63%)
Cap. Boursière: 165,68 M
Prix
6,25 €
Cap. Boursière
165,68 M
Fourchette du Jour
5,93 € — 6,32 €
Fourchette 52 Semaines
5,60 € — 15,57 €
Volume
93 972
Ouverture 6,16 €
Moyenne 50J / 200J
6,98 €
10,42% below
Moyenne 50J / 200J
8,87 €
29,52% below

Quick Summary

Points Clés

Revenue declined -57,42% annually over 5 years
Negative free cash flow of -79,40 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 35,39%
Capital intensive — 194,99% of revenue goes to capex

Croissance

Revenue Growth (5Y)
-57,42%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)-92,81%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-30,81%
Net Margin-4658,63%
Op. Margin-5127,10%

Sécurité

Debt / Equity
N/A
Current Ratio10,67
Interest CoverageN/A

Valorisation

PE (TTM)
-1,27
Au-dessus de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -1,3 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % -4658,6 -41,5
Rev Growth 5Y % -57,4 1,8
D/E — 0,3

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
1,01% weight
JMCGX JMCGX
0,53% weight
JMIGX JMIGX
0,53% weight
JSIGX JSIGX
0,47% weight
JSCGX JSCGX
0,47% weight
EES logo EES WisdomTree U.S. SmallCap Fund
0,01% weight
IRSSX IRSSX
0,00% weight
VVICX VVICX
0,00% weight
IRCIX IRCIX
0,00% weight
IIRSX IIRSX
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -92,81% Revenue Growth (3Y) -67,20%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -57,42% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2,80 M Net Income (TTM) -130,30 M
ROE N/A ROA -34,22%
Gross Margin N/A Operating Margin -5127,10%
Net Margin -4658,63% Free Cash Flow (TTM) -79,40 M
ROIC -30,81% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10,67
Interest Coverage N/A Asset Turnover 0,01
Working Capital 133,46 M Tangible Book Value -84,01 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,27 Forward P/E N/A
P/B Ratio N/A P/S Ratio 59,24
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -47,92%
Market Cap 165,68 M Enterprise Value 22,30 M
Per Share
EPS (Diluted TTM) -5,02 Revenue / Share 0,11
FCF / Share -3,00 OCF / Share -2,79
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 194,99% FCF Conversion 60,93%
SBC-Adj. FCF -89,47 M Growth Momentum -35,39

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,80 M 38,91 M 26,00 M 110,78 M 85,08 M
Net Income -130,30 M -77,42 M -219,71 M 35,38 M -25,69 M
EPS (Diluted) -5,02 -4,49 -1,66 0,10 -0,22
Gross Profit — — — — —
Operating Income -143,41 M -43,90 M -86,42 M 14,54 M -4,60 M
EBITDA — — — — —
R&D Expenses 58,03 M 45,11 M 71,84 M 72,38 M 68,74 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — 0,0 2,83 M 3,03 M 2,84 M
Income Tax -9,19 M 287 000,0 -19,00 M -609 000,0 15,97 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 296,41 M 435,02 M 305,05 M 165,89 M 159,88 M
Total Liabilities 422,65 M 441,83 M 444,68 M 72,06 M 137,36 M
Shareholders' Equity -126,24 M -6,80 M -440,18 M 93,83 M 22,52 M
Total Debt — — — — —
Cash & Equivalents 125,14 M 212,61 M 76,91 M 106,44 M 114,06 M
Current Assets 129,28 M 216,63 M 90,73 M 148,14 M 144,44 M
Current Liabilities 14,94 M 22,98 M 68,21 M 25,08 M 72,25 M